Metabolic disease models –Diabetic Cardiomyopathy Rat Model
Evaluate your therapeutics’ efficacy on metabolic disease-associated cardiovascular complications using InnoSer’s Diabetic Cardiomyopathy Rat Model
Diabetic Cardiomyopathy Rat Model Characteristics
InnoSer’s diabetic cardiomyopathy rat model represents an advanced preclinical research model designed to mimic human cardiometabolic diseases and their associated cardiovascular complications. By feeding rats, a high-fat, high-sugar western diet over an extended period, the diabetic cardiomyopathy rat model replicates the key pathophysiological processes that contribute to type 2 diabetes mellitus (T2DM) development (hyperglycemia, insulin resistance, obesity, hypertriglyceridemia) as well as associated complications, including progressive cardiac dysfunction (fibrosis, inflammation).
Depending on study durations, InnoSer’s diabetic cardiomyopathy rat model can be tailored allowing you to study pre-diabetes, T2DM and/or T2DM with associated diabetic cardiomyopathy complications. This is a predictive model to study drug efficacy in heart failure with preserved ejection fraction (HFpEF) with obesity and type 2 diabetes as key pathological causative risk factors. Therefore, this model can be used to assess your compound’s ability to prevent T2DM-induced cardiomyopathy or directly impact the varying symptoms of cardiac dysfunction arising as a result of the Western style diet. Contact us to discuss how this model can advance your research into metabolic and cardiovascular diseases.
✓ Model shows many hallmarks of T2DM and obesity (increased AGEs, hyperinsulinemia, hypertriglyceridemia, obesity, dyslipidemia, impaired glycemic control)
✓ Model shows many hallmarks of cardiomyopathy (left ventricular hypertrophy and remodeling, diastolic dysfunction, key signs of heart failure with preserved ejection fraction)
✓ The model is extensively characterized, peer reviewed and documented in literature (Verboven et al., 2018)

As a preclinical metabolic CRO, InnoSer’s team delivers you with a range of high-quality in vivo models for key metabolic diseases with different associated risk factors and aetiologies. This selection allows you to test therapeutic efficacy to prevent or reverse insulin resistance, pre-diabetes, obesity type 2 diabetes mellitus (T2DM), and/or MAFLD/MASH (NASH/NAFLD). Reach out to our team to discuss the most suitable model to answer your research questions.
Diabetic Cardiomyopathy Rat Model Sample Data

The diabetic cardiomyopathy rat model is suitable to evaluate efficacy of therapeutics on metabolic disease associated cardiovascular complications.
Fasted glycemic control oral glucose tolerance test (OGTT) differences between rats fed the Western-style diet compared to rats fed control diets.

The diabetic cardiomyopathy rat model is suitable to evaluate efficacy of therapeutics on metabolic disease associated cardiovascular complications.
Glycemic control oral glucose tolerance test (OGTT) + 60 minutes differences between rats fed the Western-style diet compared to rats fed control diets.
Diabetic Cardiomyopathy Rat Model Readouts
The People Behind Your Research
Yanick Fanton, PhD, Chief Scientific Officer
As Chief Science Officer at InnoSer, Yanick is responsible for all customer studies at InnoSer and takes care of the scientific and technical coordination.
Discover Other Related Metabolic Disease Mouse Models
Stay Curious: More Articles to Explore
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com